Detalhe da pesquisa
1.
Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.
N Engl J Med
; 390(9): 795-805, 2024 Feb 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37962077
2.
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study.
Hepatology
; 78(2): 397-415, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37386786
3.
Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSC.
Clin Gastroenterol Hepatol
; 21(6): 1552-1560.e2, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35934287
4.
A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis.
J Hepatol
; 77(2): 353-364, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35367282
5.
A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis.
Hepatology
; 74(6): 3146-3160, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34333790
6.
A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study.
Hepatology
; 74(6): 2952-2964, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34255381
7.
Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH.
Hepatology
; 73(2): 625-643, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33169409
8.
Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations.
Am J Gastroenterol
; 116(2): 254-262, 2021 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33284184
9.
Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials.
J Viral Hepat
; 28(11): 1635-1642, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34448313
10.
Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial.
Hepatology
; 72(1): 58-71, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32115759
11.
Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension.
J Hepatol
; 72(5): 885-895, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31870950
12.
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials.
J Hepatol
; 73(1): 26-39, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32147362
13.
Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy.
Gastroenterology
; 157(6): 1506-1517.e1, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31401140
14.
Financial Compensation For Hepatologists in Different Practice Settings.
Hepatology
; 69(6): 2664-2671, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30586171
15.
Has Access to Hepatitis C Virus Therapy Changed for Patients With Mental Health or Substance Use Disorders in the Direct-Acting-Antiviral Period?
Hepatology
; 69(1): 51-63, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30019478
16.
The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis.
Hepatology
; 70(3): 788-801, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30661255
17.
Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease.
Hepatology
; 69(2): 684-698, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30153359
18.
The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials.
Hepatology
; 70(6): 1913-1927, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30993748
19.
Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials.
Hepatology
; 70(5): 1521-1530, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31271665
20.
Approach to the patient with chronic hepatitis B and decompensated cirrhosis.
Liver Int
; 40 Suppl 1: 22-26, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32077612